Delivery Order SPE2DR25D3005-SPE2DR26FP8PF
- Not listed
- The Defense Logistics Agency awarded a $4,994.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10s. This competitively awarded, non-set-aside contract is scheduled for completion by January 8, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite...
- The Defense Logistics Agency awarded a $2,995.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packages of 10. This non-set-aside contract, which will be completed by January 7, 2026, represents a routine pharmaceutical procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging (10s). The contract is valued at $14,926.77 with a completion date of January 8, 2026, and is structured as a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a $4,007.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10 tablets. This contract, which is non-set-aside and competitively awarded, will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 8, 2026. The delivery order is issued under AmerisourceBergen's parent...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,388.84 to supply Oseltamivir Phosphate 75 mg capsules in unit dose packages of 10 units. The order was competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of December 19, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- On January 13, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $2,533.78 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10 tablets. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 14, 2026. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,336.25 to AmerisourceBergen Drug Corp on January 8, 2026, for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packaging of 10s. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract is scheduled for completion by January 9, 2026, and performance will be executed from the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Oseltamivir Phosphate 75 mg capsules (100-count packages) with a ceiling value of $1,890.00. This firm fixed-price delivery order is set to be completed by December 12, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitive award with no set-aside designation, issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,991.36 to AmerisourceBergen Drug Corp for oseltamivir phosphate 75 mg capsules in unit-dose packages of 10, with an ultimate completion date of January 6, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,246.76 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules in unit dose packs of 10 on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP8PFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,540.43 to AmerisourceBergen Drug Corp for the supply of Oseltamivir Phosphate 75 mg capsules (100-count packaging) on January 13, 2026, with an ultimate completion date of January 14, 2026. This is a firm fixed-price contract with no set-aside designation, indicating open competition. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and pharmaceutical distribution hub. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a substantial $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical running through December 31, 2031. This primary contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Oseltamivir, an antiviral medication, represents one of the critical pharmaceutical commodities delivered under this broader federal medical supply agreement to support military treatment facilities and veterans' healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 1/12/26 |